We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalti... Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. Show more
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class...
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowenβs 44th Annual Health Care Conference on...
Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023Announced...
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.44 | 1.59767610748 | 27.54 | 28.4 | 27.21 | 2721007 | 27.84082097 | CS |
4 | -2.44 | -8.02103879027 | 30.42 | 30.8 | 27.21 | 2596811 | 28.74416712 | CS |
12 | -0.72 | -2.50871080139 | 28.7 | 31.655 | 27.21 | 2846997 | 29.59988267 | CS |
26 | 0.48 | 1.74545454545 | 27.5 | 31.655 | 26.07 | 2573444 | 28.74640321 | CS |
52 | -8.14 | -22.5359911406 | 36.12 | 36.19 | 25.92 | 2432084 | 29.646871 | CS |
156 | -16.02 | -36.4090909091 | 44 | 47.1 | 25.92 | 2117066 | 36.13206364 | CS |
260 | -17.92 | -39.0413943355 | 45.9 | 57.5 | 25.92 | 2139115 | 38.26929764 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions